Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics

Brzaković, Branka; Kovačević, Sandra D Vezmar; Vučićević, Katarina; Miljković, Branislava; Martinović, Žarko; Pokrajac, M.; Prostran, Milica

doi:10.1111/j.1365-2710.2012.01351.x

Cited by 35 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma concentrations of lamotrigine were measured using a high performance liquid chromatography method described by Brzakovi c et al 10 The detection limit was 0.04 mmol/L using 0.5 mL of plasma, and the coefficients of variation were 6.57% 6 2.01% for between-day imprecision and was 4.95% 6 1.87% for within-day imprecision.…”

Section: Methodsmentioning

confidence: 99%

Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Kagawa

Mihara

Nakamura

et al. 2014

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Kagawa

Mihara

Nakamura

et al. 2014

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…Carbamazepine, PHT and PB also induce CYP1A2, CYP2C9, CYP2C19 and CYP3A4 activities, as well as the glucuronyl transferases (including UGT1A4), while VPA inhibits these enzymes' activities (Perucca, 2005;Johannessen, Landmark, 2010;Brzakovic et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Influence of the clinical profile of patients with refractory epilepsy on lamotrigine plasma concentration

Baldoni

Freitas‐Lima

Alexandre

et al. 2018

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

The purpose of this work was to evaluate the influence of the clinical profile on lamotrigine (LTG) plasma concentrations from patients with refractory epileptic seizures. In this cross-sectional study, therapeutic monitoring of LTG, and questionnaires with 75 patients with refractory epileptic seizures of a Hospital in Ribeirão Preto-SP-Brazil were performed. The multiple linear regression model was used to verify association between the LTG plasma concentrations and the independent variables. Covariance analysis was used to compare the mean LTG plasma concentration among the co-medication groups. The LTG plasma concentration was associated both with the LTG dosage (mg/kg/day) (p=0.0096) and with the use of first generation antiepileptic drugs (AED) (p<0.01), being carbamazepine (CBZ) and phenytoin (PHT), the AEDs showing the most prominent influence in reducing LTG plasma concentrations. Adverse events, adherence to the pharmacological treatment, and epileptic seizures frequency, did not show significant correlation with LTG plasma concentration values. The conclusion is that LTG plasma concentration is significantly influenced by the LTG dosage and by the concomitant use of a first generation AED.

show abstract

“…Plasma concentrations of lamotrigine were measured using the high-performance liquid chromatography method described by Brzaković et al [18]. …”

Section: Methodsmentioning

confidence: 99%

Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

et al. 2017

View full text Add to dashboard Cite

Background/Aims: Serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) were prospectively monitored in relation with therapeutic response to lamotrigine augmentation therapy in 46 (15 males and 31 females) inpatients with treatment-resistant depressive disorder during an 8-week treatment with lamotrigine using an open-study design. Methods: The subjects were 46 depressed patients who had already shown insufficient response to at least 3 psychotropics including antidepressants, mood stabilizers, and atypical antipsychotics. The diagnoses were major depressive disorder (n = 19), bipolar I disorder (n = 6), and bipolar II disorder (n = 22). The final doses of lamotrigine were 100 mg/day for 26 subjects who were not taking valproate and 75 mg/day for 20 subjects taking valproate, respectively. Depressive symptoms were evaluated by the Montgomery-Åsberg Depression Rating Scale (MADRS) before and after the 8-week treatment. Blood sampling was performed before the start of lamotrigine treatment and at week 8. Serum BDNF and IL-6 levels were measured using quantitative sandwich enzyme immunoassays. Results: No significant changes in serum BDNF or IL-6 levels during the 8-week lamotrigine treatment were observed in the total of subjects, responders or nonresponders. There was no significant correlation between the changes in serum BDNF or IL-6 levels and the percent improvement in MADRS scores in the overall subjects. Conclusion: The present study suggests that the acute effect of lamotrigine augmentation therapy for a major depressive episode is not related to either BDNF or IL-6, at least in patients with treatment-resistant depressive disorder.

show abstract

Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics

Cited by 35 publications

References 34 publications

Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Influence of the clinical profile of patients with refractory epilepsy on lamotrigine plasma concentration

Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Contact Info

Product

Resources

About